 CAMBRIDGE, Mass.--BUSINESS WIRE--- VBIV--VBI Vaccines Inc. Nasdaq: VBIV VBI, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a Biologics License Application BLA to the U.S. Food and Drug Administration FDA seeking approval of the Companys 3-antigen prophylactic hepatitis B vaccine candidate, for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults. 